Spots Global Cancer Trial Database for icotinib

Every month we try and update this database with for icotinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation	NCT02961270	Non-small Cell ...	Icotinib	18 Years - 75 Years	ChineseAMS
Icotinib for Completed Resected IB NSCLC With EGFR Mutation	NCT02264210	Lung Neoplasms Squamous Cell L... Adenocarcinoma ... Adenosquamous C... Large Cell Lung... Bronchial Neopl... Stage IB Non-sm...	Icotinib	18 Years - 75 Years	Sun Yat-sen University
Evaluation of Icotinib in Metastatic Triple-negative Breast Cancer After Second-line Therapy	NCT02362230	Metastatic Brea...	Icotinib	18 Years - 65 Years	Sun Yat-sen University
Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer	NCT05007938	Non-Small Cell ...	Icotinib Befotertinib	18 Years -	Betta Pharmaceuticals Co., Ltd.
Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy	NCT01720901	Non-small Cell ...	Icotinib	18 Years - 70 Years	Betta Pharmaceuticals Co., Ltd.
Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation	NCT02961270	Non-small Cell ...	Icotinib	18 Years - 75 Years	ChineseAMS
Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer	NCT02024633	Pancreatic Canc...	icotinib Gemcitabine	18 Years - 70 Years	Betta Pharmaceuticals Co., Ltd.
Icotinib in Advanced Non-small Cell Lung Cancer (NSCLC) With Hepatic Insufficiency	NCT02062515	Non-small Cell ...	icotinib	18 Years - 75 Years	Betta Pharmaceuticals Co., Ltd.
Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer	NCT03749213	EGF-R Positive ...	Icotinib	18 Years - 70 Years	Betta Pharmaceuticals Co., Ltd.
A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer	NCT05104788	Non-Small Cell ...	Icotinib Cisplatin Carboplatin Pemetrexed	18 Years - 75 Years	Peking University Cancer Hospital & Institute
Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer	NCT02024633	Pancreatic Canc...	icotinib Gemcitabine	18 Years - 70 Years	Betta Pharmaceuticals Co., Ltd.
Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma	NCT01665417	EGFR Positive N... Adenocarcinoma	Experimental Chemotherapy Chemotherapy	18 Years - 70 Years	Betta Pharmaceuticals Co., Ltd.
Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC	NCT04797806	Non Small Cell ...	Anlotinib Icotinib	18 Years - 75 Years	Tianjin Medical University Cancer Institute and Hospital
Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation	NCT02961270	Non-small Cell ...	Icotinib	18 Years - 75 Years	ChineseAMS
First-line Icotinib With Concurrent Radiotherapy for NSCLC With EGFR Mutation	NCT02883543	Non-small Cell ...	icotinib Chemotherapy Radiotherapy	18 Years - 75 Years	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer	NCT03396185	EGFR Gene Mutat... Non Small Cell ... Non Small Cell ...	Icotinib	18 Years - 75 Years	Betta Pharmaceuticals Co., Ltd.
Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation	NCT01516983	Non-small Cell ... Brain Metastase...	icotinib Whole brain rad...	18 Years - 75 Years	Betta Pharmaceuticals Co., Ltd.
Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation	NCT03754530	Non-Small Cell ... Brain Metastase...	Icotinib WBRT or SRS	18 Years - 75 Years	Betta Pharmaceuticals Co., Ltd.
Adjuvant Chemotherapy With or Without Intercalated Icotinib	NCT03983811	Carcinoma, Non-...	Icotinib Placebo chemotherapy	18 Years - 75 Years	Nanfang Hospital, Southern Medical University
Bevacizumab Combined With Double Dose Icotinib in Patients With EGFR Exon 21-L858R Mutation	NCT05263947	Carcinoma, Non-... Bevacizumab EGF-R Positive ... Tyrosine Kinase...	Bevacizumab and...	18 Years - 75 Years	Tianjin Medical University Cancer Institute and Hospital
Intermittent and Maintenance of Icotinib in Combination With Pemetrexed/Carboplatin Compared With Icotinib Single Drug in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation	NCT03151161	Lung, Carcinoma	Icotinib,Pemetr... Icotinib	18 Years - 75 Years	Sun Yat-sen University
Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer	NCT02278458	Pancreatic Canc...	icotinib Gemcitabine	18 Years - 70 Years	Betta Pharmaceuticals Co., Ltd.
Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients	NCT01843647	Non-small-cell ...	Icotinib Chemotherapy	18 Years - 70 Years	Betta Pharmaceuticals Co., Ltd.
First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients	NCT01646450	Non-Small Cell ...	Icotinib	70 Years - 80 Years	Betta Pharmaceuticals Co., Ltd.
Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With EGFR Gene Mutation	NCT02283424	Neoplasms, Ther...	Icotinib chemotherapy (C...	18 Years - 75 Years	Chinese PLA General Hospital
Cryotherapy Combine Icotinib for Advanced NSCLC Treatment	NCT02744664	Lung Neoplasms	Cryotherapy Icotinib	18 Years - 75 Years	Fuda Cancer Hospital, Guangzhou
Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer	NCT03349203	EGF-R Positive ...	Icotinib	18 Years - 70 Years	Betta Pharmaceuticals Co., Ltd.
High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation	NCT02404675	NSCLC	icotinib	18 Years - 75 Years	Betta Pharmaceuticals Co., Ltd.
Phase II Study of Icotinib With Concurrent Radiotherapy in Elderly Patients With Esophageal Cancer	NCT02375581	Esophageal Canc...	Icotinib Thoracic radiot...	70 Years - 85 Years	First People's Hospital of Hangzhou
Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma	NCT02103257	EGFR Positive N... Adenocarcinoma	Sequential Icot... Icotinib	18 Years - 75 Years	Betta Pharmaceuticals Co., Ltd.
Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study	NCT04575415	NSCLC	Bevacizumab Erlotinib Gefitinib Icotinib Afatinib Dacomitinib Osimertinib	18 Years - 75 Years	Guangdong Association of Clinical Trials
Icotinib in Previously Treated Non/Light-smoking Patients With Advanced Squamous Cell Lung Cancer	NCT02009605	Squamous Cell C...	Icotinib	18 Years - 75 Years	Zhejiang University
Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI	NCT02066870	Non-small Cell ...	Icotinib Arsenic trioxid...	18 Years - 75 Years	Betta Pharmaceuticals Co., Ltd.
Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma	NCT05132985	NSCLC EGF-R Positive ...	Icotinib Cisplatin Carboplatin Pemetrexed	18 Years - 75 Years	Liaoning Tumor Hospital & Institute
Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation	NCT02044328	Non-small Cell ...	Icotinib	18 Years - 75 Years	Betta Pharmaceuticals Co., Ltd.
Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors	NCT02934256	Vestibular Schw... Neurofibromatos...	Icotinib	16 Years - 50 Years	Beijing Tiantan Hospital
Phase II Clinical Study of Intermittent High Dose of Icotinib in Combination With Docetaxel to Treat Lung Cancer	NCT02191059	Non Small Cell ...	Icotinib Docetaxel	18 Years - 70 Years	Shandong Cancer Hospital and Institute
Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation	NCT02448797	Non-small Cell ...	Icotinib Chemotherapy	18 Years - 70 Years	Betta Pharmaceuticals Co., Ltd.
Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer	NCT03749213	EGF-R Positive ...	Icotinib	18 Years - 70 Years	Betta Pharmaceuticals Co., Ltd.
Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients	NCT01040780	Non-small Cell ...	Icotinib Gefitinib	18 Years - 75 Years	Betta Pharmaceuticals Co., Ltd.
High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC	NCT02960607	Carcinoma, Non-...	Icotinib	18 Years - 75 Years	ChineseAMS
High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases	NCT02726568	Non-small Cell ... Brain Metastase...	Icotinib SRS	18 Years - 75 Years	Betta Pharmaceuticals Co., Ltd.
First-line Icotinib With Concurrent Radiotherapy for NSCLC With EGFR Mutation	NCT02883543	Non-small Cell ...	icotinib Chemotherapy Radiotherapy	18 Years - 75 Years	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Icotinib With Concurrent Radiotherapy vs. Chemoradiotherapy in Non-small Cell Lung Cancer	NCT02407366	Non-small Cell ...	Icotinib Pemetrexed Carboplatin Thoracic radiot...	18 Years - 75 Years	People's Hospital of Guangxi
Icotinib or Whole Brain Irradiation in EGFR-mutant Lung Cancer	NCT01724801	Brain Metastasi... Non Small Cell ...	whole brain rad... Icotinib	18 Years - 75 Years	Guangdong Association of Clinical Trials
Phase II Study of Icotinib With Concurrent Radiotherapy in Elderly Patients With Esophageal Cancer	NCT02375581	Esophageal Canc...	Icotinib Thoracic radiot...	70 Years - 85 Years	First People's Hospital of Hangzhou
Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With Chemotherapy	NCT02486354	Non-small Cell ...	icotinib	18 Years - 75 Years	Betta Pharmaceuticals Co., Ltd.
Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer	NCT02031601	Non-Small-Cell ...	Erlotinib Gefitinib Icotinib Docetaxel Pemetrexed Platinum (cispl... Erlotinib Gefitinib Icotinib	18 Years - 80 Years	Qilu Hospital of Shandong University
Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer	NCT02278458	Pancreatic Canc...	icotinib Gemcitabine	18 Years - 70 Years	Betta Pharmaceuticals Co., Ltd.
Icotinib Combined With Whole Brain Radiotherapy in Treating Multiple Brain Metastases From Non-Small Cell Lung Cancer	NCT01514877	Lung Cancer Metastatic Canc...	Icotinib	18 Years - 75 Years	Zhejiang Cancer Hospital
Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer	NCT03766490	Non-Small-Cell ...	Anlotinib Hydro... Gefitinib Icotinib	18 Years - 75 Years	The First Affiliated Hospital of Soochow University
Phase II Trial of Double Dose of Icotinib in Treating Brain Metastases From Non-small Cell Lung Cancer	NCT01688713	Brain Metastase... Non-small Cell ...	Icotinib	18 Years - 75 Years	Zhejiang Cancer Hospital
Phase II Clinical Study of Intermittent High Dose of Icotinib in Combination With Docetaxel to Treat Lung Cancer	NCT02191059	Non Small Cell ...	Icotinib Docetaxel	18 Years - 70 Years	Shandong Cancer Hospital and Institute
Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose	NCT01465243	Non-small Cell ...	Icotinib	18 Years - 75 Years	Betta Pharmaceuticals Co., Ltd.
Chemotherapy of NSCLC With or Without Icotinib	NCT02430974	Carcinoma, Non-...	Icotinib	18 Years -	Nanfang Hospital, Southern Medical University
Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer	NCT02031601	Non-Small-Cell ...	Erlotinib Gefitinib Icotinib Docetaxel Pemetrexed Platinum (cispl... Erlotinib Gefitinib Icotinib	18 Years - 80 Years	Qilu Hospital of Shandong University
Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With Chemotherapy	NCT02486354	Non-small Cell ...	icotinib	18 Years - 75 Years	Betta Pharmaceuticals Co., Ltd.
Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients	NCT01040780	Non-small Cell ...	Icotinib Gefitinib	18 Years - 75 Years	Betta Pharmaceuticals Co., Ltd.
Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma	NCT02125240	EGFR Positive N... Adenocarcinoma	Icotinib Placebo	18 Years - 75 Years	Betta Pharmaceuticals Co., Ltd.
Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations.	NCT03992885	Non-squamous No...	Icotinib	18 Years - 75 Years	Tianjin Medical University Cancer Institute and Hospital
Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy	NCT01720901	Non-small Cell ...	Icotinib	18 Years - 70 Years	Betta Pharmaceuticals Co., Ltd.
Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma	NCT01534585	Nasopharyngeal ...	Icotinib intensity-modul... Paclitaxel and ... Quality of life Epidermal growt...	18 Years - 70 Years	Taizhou Hospital
Evaluation of Icotinib in Metastatic Triple-negative Breast Cancer After Second-line Therapy	NCT02362230	Metastatic Brea...	Icotinib	18 Years - 65 Years	Sun Yat-sen University
Icotinib in Previously Treated Non/Light-smoking Patients With Advanced Squamous Cell Lung Cancer	NCT02009605	Squamous Cell C...	Icotinib	18 Years - 75 Years	Zhejiang University
Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma	NCT02125240	EGFR Positive N... Adenocarcinoma	Icotinib Placebo	18 Years - 75 Years	Betta Pharmaceuticals Co., Ltd.
Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients	NCT01719536	NSCLC	Icotinib Chemotherapy	18 Years - 75 Years	Betta Pharmaceuticals Co., Ltd.
Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients	NCT01719536	NSCLC	Icotinib Chemotherapy	18 Years - 75 Years	Betta Pharmaceuticals Co., Ltd.
A Phase II Study of Icotinib in Treating Patients With Advanced Nasopharyngeal Carcinoma	NCT02328261	Nasopharyngeal ...	Icotinib	18 Years - 75 Years	Betta Pharmaceuticals Co., Ltd.
Study of Chemotherapy Plus Icotinib to Treat EGFR Mutation-positive Non-small-cell Lung Cancer	NCT02272127	NSCLC	icotinib	18 Years -	Nanfang Hospital, Southern Medical University
First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients	NCT01646450	Non-Small Cell ...	Icotinib	70 Years - 80 Years	Betta Pharmaceuticals Co., Ltd.
Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose	NCT01465243	Non-small Cell ...	Icotinib	18 Years - 75 Years	Betta Pharmaceuticals Co., Ltd.
Efficiency of Icotinib in Plasma ctDNA EGFR Mutation-positive Patients Diagnosed With Lung Cancer	NCT03346811	Plasma EGFR Mut...	Icotinib	18 Years -	Betta Pharmaceuticals Co., Ltd.
A Phase II Study of Icotinib in Treating Patients With Advanced Nasopharyngeal Carcinoma	NCT02328261	Nasopharyngeal ...	Icotinib	18 Years - 75 Years	Betta Pharmaceuticals Co., Ltd.
Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer	NCT02278458	Pancreatic Canc...	icotinib Gemcitabine	18 Years - 70 Years	Betta Pharmaceuticals Co., Ltd.
Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy	NCT01720901	Non-small Cell ...	Icotinib	18 Years - 70 Years	Betta Pharmaceuticals Co., Ltd.
Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI	NCT02066870	Non-small Cell ...	Icotinib Arsenic trioxid...	18 Years - 75 Years	Betta Pharmaceuticals Co., Ltd.
Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC	NCT04797806	Non Small Cell ...	Anlotinib Icotinib	18 Years - 75 Years	Tianjin Medical University Cancer Institute and Hospital
Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer	NCT03766490	Non-Small-Cell ...	Anlotinib Hydro... Gefitinib Icotinib	18 Years - 75 Years	The First Affiliated Hospital of Soochow University
Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH	NCT01855854	Adenocarcinoma ... Esophageal Carc...	Icotinib	18 Years - 75 Years	Betta Pharmaceuticals Co., Ltd.

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world:

Spots Global Cancer Trial Database for icotinib

Every month we try and update this database with for icotinib cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for icotinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.